Welcome to our dedicated page for 2Seventy Bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2Seventy Bio stock.
2seventy bio, Inc. (Nasdaq: TSVT) is an immuno-oncology cell therapy company centered on Abecma (idecabtagene vicleucel; ide-cel), a BCMA-directed autologous CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma after at least two prior lines of therapy. The TSVT news stream features company announcements that combine scientific, commercial, and corporate developments related to this program and its broader collaboration with Bristol Myers Squibb (BMS).
Investors and observers following TSVT news will find regular updates on Abecma’s U.S. commercial performance, including quarterly and full-year revenues as reported by BMS, trends in demand such as patients undergoing apheresis, and commentary on Abecma’s role in the multiple myeloma treatment landscape. Releases also discuss regulatory milestones, label expansions into earlier-line settings, and decisions around clinical studies such as the discontinuation of enrollment in the Phase 3 KarMMa-9 trial in newly diagnosed multiple myeloma.
Corporate and financial news for 2seventy bio includes quarterly earnings reports, changes in operating expenses, net cash spend, and cash, cash equivalents, and marketable securities. The company has reported transactions such as the sale of its oncology R&D business to Regeneron and the sale of its Hemophilia A program and gene editing technology to Novo Nordisk, which it characterizes as supporting an exclusive focus on Abecma. Conference participation and investor events, including healthcare conferences and fireside chats, are also covered in TSVT news items.
A key current theme in 2seventy bio’s news is its definitive merger agreement with Bristol Myers Squibb. News releases describe the agreed all-cash acquisition, the tender offer structure, the Hart-Scott-Rodino review process, and the expectation that, following completion of the transaction and a second-step merger, 2seventy bio’s common stock will no longer trade on Nasdaq. For readers tracking TSVT, the news page provides an evolving record of Abecma’s commercial trajectory, strategic partnerships, and the company’s pending transition into BMS.
2seventy bio (Nasdaq: TSVT) has announced it will release its second quarter 2024 financial results on August 7, 2024. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the call via webcast on the company's website or register for dial-in details. 2seventy bio is known for developing the first FDA-approved CAR T cell therapy for multiple myeloma. The company's name reflects its mission to work at maximum speed (270 miles per hour) to give cancer patients more time. 2seventy bio focuses on understanding the human body's immune response to tumor cells and translating cell therapies into practice.
2seventy bio (Nasdaq: TSVT) has finalized an asset purchase agreement with Novo Nordisk, selling its Hemophilia A program and in vivo gene editing technology for up to $40 million. The divestiture includes the transfer of related intellectual property and the team working on the program to Novo Nordisk. This move allows 2seventy bio to concentrate exclusively on the development and commercialization of Abecma, its BCMA-targeted CAR T cell therapy for multiple myeloma, in partnership with Bristol Myers Squibb. Novo Nordisk aims to advance the Hemophilia A program, leveraging the megaTAL technology.
2seventy bio (Nasdaq: TSVT) has announced its participation in upcoming investor conferences. The management team will present at the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. These events will include virtual fireside chats, available via live webcasts on the company's website, with replays accessible for 30 days. 2seventy bio focuses on developing CAR T cell therapies for multiple myeloma, leveraging their deep understanding of immune responses to tumor cells. Their name reflects their mission to rapidly translate human thought into action, aiming to extend the lives of cancer patients.
2seventy bio, Inc. (Nasdaq: TSVT) reported Q1 2024 financial results and operational progress, focusing on Abecma, generating $52 million in U.S. commercial revenue. The FDA approved Abecma for treating relapsed or refractory multiple myeloma, expanding potential patient eligibility. Despite a decrease in total revenues, operational restructuring and cost optimization aim to drive future growth and shareholder value. The company ended the quarter with $181.4 million in cash, cash equivalents, and marketable securities, ensuring financial sustainability beyond 2027.
2seventy bio, Inc. (Nasdaq: TSVT) will report its first quarter 2024 financial results on May 8, 2024. The company aims to accelerate cancer treatment development by leveraging cell therapies. They focus on delivering the first FDA-approved CAR T cell therapy for multiple myeloma. 2seventy bio emphasizes speed and efficacy in translating human thought into action, aiming to give patients more time. The company maintains a genuine approach and prioritizes its people and culture.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of 2Seventy Bio (TSVT)?
What is the market cap of 2Seventy Bio (TSVT)?
